Clinical trial · no report yet · Phase 2
NEOpredict
Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients
- NCT04205552 ↗
- Completed
- University Hospital, Essen
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 5 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients: Defining Optimal Combinations and Determinants of Immunological Response
- Phase
- Phase 2
- Status
- Completed
- Conditions
- NSCLC Stage II; NSCLC, Stage IIIA; NSCLC, Stage I
- Interventions
- Nivolumab 10 MG/ML Intravenous Solution; Relatlimab 10 MG/ML Intravenous Solution
- Arms
- Nivolumab · Experimental
- Nivolumab/Relatlimab (80 mg) · Experimental
- Nivolumab/Relatlimab (240 mg) · Experimental
- Enrollment
- 90
- Primary outcomes
- Feasibility of four weeks of preoperative immunotherapy with Nivolumab, Nivolumab plus Relatlimab (80 mg), and Nivolumab plus Relatlimab (240 mg)
- Sponsor
- University Hospital, Essen
- Start
- Mar 4, 2020
- Primary completion
- Nov 27, 2025
- Results posted
- No
- Registry record
- NCT04205552 · updated Jun 11, 2026
Publications
linked from the registry- Schuler M, Cuppens K, Plones T, Wiesweg M, Du Pont B, Hegedus B, Koster J, Mairinger F, Darwiche K, Paschen A, Maes B, Vanbockrijck M, Lahnemann D, Zhao F, Hautzel H, Theegarten D, Hartemink K, Reis H, Baas P, Schramm A, Aigner C. Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial. Nat Med. 2024 Jun;30(6):1602-1611. doi: 10.1038/s41591-024-02965-0. Epub 2024 Apr 30. PubMed 38689060